Please ensure Javascript is enabled for purposes of website accessibility

Cell Therapeutics' Wild Week

By Dave Williamson – Updated Apr 6, 2017 at 10:58AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The following video is part of our "Motley Fool Conversations" series, in which, Andrew Tonner, technology editor and analyst, and David Williamson, health-care editor and analyst, discuss topics across the investing world.

In today's edition, they discuss Cell Therapeutics, which has had a roller coaster of a week. After receiving word that its lead drug candidate, pixantrone, had been accepted for FDA review, shares gained 24%. Unfortunately for investors, the company used the higher share price to announce an equity offering worth $20 million, sending shares plummeting back down. Our Motley Fool analysts discuss the news and examine what approval of pixantrone could mean for investors.

Looking for our prediction for 2012? Check out The Motley Fool's brand new report, "The Motley Fool's Top Stock for 2012." It highlights a company that's revolutionizing commerce in Latin America. You can get instant access to the name of this company by clicking here -- it's free.

Andrew Tonner and David Williamson own no shares of the companies mentioned here. The Motley Fool owns shares of Dendreon. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.